

TABLE 205: FATIGUE

AUTHOR, YEAR, STUDY NAME	GENOTYPE	TREATMENT	n	N	%
Afdhal et al., 2014 ION-2	1	(6) SOF12 + LDV12	23	109	21%
		(10) SOF12 + LDV12 + RBV12	45	111	41%
		(7) SOF24 + LDV24	26	109	24%
		(11) SOF24 + LDV24 + RBV24	50	111	45%
Andreone et al., 2014 PEARL-II	1b	(14) PAR/RIT12 + OMB12 + DAS12	15	95	16%
Bacon et al., 2011 RESPOND2	1	(1) PR48	40	80	50%
		(74) B32 PR36-48 RGT	87	162	54%
Bourlière et al., 2015 SIRIUS	1	(7) SOF24 + LDV24	15	77	19%
		(10) SOF12 + LDV12 + RBV12	7	78	9%
Forns et al., 2015 C-SALVAGE	1	(23) GRZ12 + ELB12 + RBV12	22	79	28%
Gane et al., 2013-2 ELECTRON	1	(3) SOF12 + RBV12	4	10	40%
Gane et al., 2014-2 ELECTRON	1	(10) SOF12 + LDV12 + RBV12	7	9	78%
Gane et al., 2014-3 ELECTRON	1	(10) SOF12 + LDV12 + RBV12	1	9	11%
Forns et al., 2014 PROMISE	1	(1) PR48	58	133	44%
		(42) SIM12 PR24-48 RGT	84	260	32%
Jacobson et al., 2013 FUSION	2+3	(3) SOF12 + RBV12	46	103	45%
Jensen et al., 2015 HALLMARK-QUAD	1+4	(18) DCV24 + ASU24 + PR24	165	398	41%
Lawitz et al., 2014	2+3	(40) SOF12 + PR12	15	47	32%

AUTHOR, YEAR, STUDY NAME	GENOTYPE	TREATMENT	n	N	%
Lawitz et al., 2014 LONESTAR	1	(6) SOF12 + LDV12	0	19	0%
Lawitz et al., 2014 LONESTAR	1	(10) SOF12 + LDV12 + RBV12	0	21	0%
Lawitz et al., 2015 C-WORTHY-4	1	(57) GRZ12 + ELB12 (50 mg q.d.)	9	33	27%
		(59) GRZ18 + ELB18 (50 mg q.d.)	8	32	25%
		(63) GRZ12 + ELB12 (50 mg q.d.) + RBV12	6	32	19%
		(65) GRZ18 + ELB18 (50 mg q.d.) + RBV18	15	33	45%
Lok et al., 2014 DUAL A2	1b	(17) DCV24 + ASU24	2	20	10%
Lok et al., 2014 QUAD B2	1	(18) DCV24 + ASU24 + PR24	5	21	24%
Manns et al., 2014 HALLMARK-DUAL	1b	(17) DCV24 + ASU24	45	205	22%
Molina et al., 2015 PHOTON-2	2+3	(4) SOF24 + RBV24	11	55	20%
Osinusi et al., 2014 SYNERGY	1	(6) SOF12 + LDV12	0	14	0%
Pol et al., 2015 NA	1	(40) SOF12 + PR12	34	80	43%
Reddy et al., 2015 ATTAIN	1	(39) T12 PR48 q8	146	384	38%
		(68) SIM12 PR48	120	379	32%
Sulkowski et al., 2014-3	2+3	(4) SOF24 + RBV24	19	41	46%
Wyles et al., 2015	1	(10) SOF12 + LDV12 + RBV12	13	51	25%
Zeuzem et al., 2014 SAPPHIRE-II	1	(15) PAR/RIT12 + OMB12 + DAS12 + RBV12	99	297	33%
Zeuzem et al., 2011 REALIZE	1	(1) PR48	53	132	40%
		(39) T12 PR48 q8	145	266	55%
Zeuzem et al., 2014 ASPIRE	1	(1) PR48	29	66	44%
		(68) SIM12 PR48	26	66	39%

ASU = asunaprevir; B = boceprevir; BEC = beclabuvir; b.i.d. = twice daily; DAS = dasabuvir; DCV = daclatasvir; ELB = elbasvir; GRZ = grazoprevir; LDV = ledipasvir; OMB = ombitasvir; PAR = paritaprevir; PR = pegylated interferon plus ribavirin; q8 = every 8 hours; q.d. = once daily; RBV = ribavirin; RGT = response-guided therapy; RIT = ritonavir; SIM = simeprevir; SOF = sofosbuvir; T = telaprevir.

Note: Please refer to Treatment Regimen Nomenclature table for description of dosages.